Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 8:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 1,598 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Major Depressive Disorder \(MDD Clear all
Terminated No phase listed Observational

Social Cognition in Longstanding Psychosis

NCT01624831
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Bipolar Disorder With Psychotic Features, Major Depression With Psychotic Features, Psychosis Not Otherwise Specified (NOS)
Interventions
Not listed
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 75 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated May 21, 2020 · Synced Oct 10, 2026, 8:15 PM EDT
Active, not recruiting Phase 3 Interventional

Psilocybin for Major Depressive Disorder (MDD)

NCT06308653
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Psilocybin 25 mg, Inactive Placebo, Psilocybin 5 mg, Psychosocial Support
Drug · Behavioral
Lead sponsor
Usona Institute
Other
Eligibility
18 Years and older
Enrollment
238 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
29
States / cities
Birmingham, Alabama • Fayetteville, Arkansas • Little Rock, Arkansas + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Oct 10, 2026, 8:15 PM EDT
Completed Phase 4 Interventional Results available

Aripiprazole Augmentation of SSRI Therapy in Treatment Refractory Depression

NCT00608543
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Aripiprazole
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 26, 2012 · Synced Oct 10, 2026, 8:15 PM EDT
Completed Not applicable Interventional

A Megastudy of Single-Session Interventions for Depression

NCT06856668
View directory record Official record
Conditions
Depression - Major Depressive Disorder
Interventions
Behavioral Activation (Action Brings Change Project 10-Minute Version), Mindful Acceptance, Moral Elevation, Mindful Attention Skills, 5 Habits to Beat Depression, Interactive Cognitive Reappraisal, Expressive Writing (AI-supported), Inner Child Healing Walk, Savoring Strategies, Personalized Intervention Recommender, Dialectical Behavioral Therapy Skills, All about Trout, Reframing Negative Thoughts
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
7,505 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 27, 2025 · Synced Oct 10, 2026, 8:15 PM EDT
Completed No phase listed Observational

Cortical Excitability and Inhibition in MDD

NCT01718730
View directory record Official record
Conditions
Major Depressive Disorder, Recurrent, Mild, Depressive Disorder, Major
Interventions
Transcranial Magnetic Stimulation (TMS), Magnetic Resonance Spectroscopy and Imaging
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
13 Years to 21 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 22, 2019 · Synced Oct 10, 2026, 8:15 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Placebo Effects in the Treatment of Depression: Cognitive and Neural Mechanisms

NCT01919216
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Citalopram
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
24 Years to 75 Years · Female only
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 9, 2020 · Synced Oct 10, 2026, 8:15 PM EDT
Recruiting Early Phase 1 Interventional

Synaptic Mechanisms of Continuous Theta Burst Stimulation in Depression

NCT07560878
View directory record Official record
Conditions
Major Depression
Interventions
D-Cycloserine (DCS), Continuous theta-burst stimulation (cTBS), Transcranial Magnetic Stimulation Sham, Memantine, Lorazepam (drug), Baclofen, Placebo
Drug · Device
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Oct 10, 2026, 8:15 PM EDT
Completed Not applicable Interventional

Sequential Bilateral Accelerated Theta Burst Stimulation in Adolescents With Suicidal Ideation

NCT04502758
View directory record Official record
Conditions
Suicidal Ideation, Major Depressive Disorder
Interventions
MagVenture TMS Therapy System w/Theta Burst Stimulation, Sham MagVenture TMS Therapy System w/Theta Burst Stimulation
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
12 Years to 18 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 10, 2026, 8:15 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate SAGE-217 in Adult Participants With Major Depressive Disorder (MDD)

NCT03864614
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
SAGE-217
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,515 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
52
States / cities
Dothan, Alabama • Phoenix, Arizona • Anaheim, California + 43 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2024 · Synced Oct 10, 2026, 8:15 PM EDT
Recruiting Phase 2 Interventional

Precision Depression Adalimumab Trial

NCT07845604
View directory record Official record
Conditions
Major Depressive Disorder (MDD)
Interventions
Adalimumab Biosimilars Injection, Placebo
Drug · Other
Lead sponsor
Daniel Moriarity
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 10, 2026, 8:15 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Multiple Ascending Oral Dose Evaluation of the Safety, Tolerability, and Pharmacokinetics of DSP-1053 and Its Metabolites in Healthy Subjects and in Subjects With Major Depressive Disorder

NCT01774747
View directory record Official record
Conditions
Healthy
Interventions
DSP-1053, Placebo
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Jun 18, 2014 · Synced Oct 10, 2026, 8:15 PM EDT
Completed Not applicable Interventional

Stress Management and Resiliency Training for Depression vs Treatment as Usual in the Treatment of Major Depression

NCT04388748
View directory record Official record
Conditions
Major Depression
Interventions
Stress Management and Resiliency Training for Depression (SMART-D) Therapy
Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
25 Years to 80 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
3
States / cities
Albert Lea, Minnesota • Austin, Minnesota • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 23, 2023 · Synced Oct 10, 2026, 8:15 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

MicroRNA Correlates of Childhood Maltreatment and Suicidality

NCT04923685
View directory record Official record
Conditions
Major Depressive Disorder, Suicidal Ideation
Interventions
Trier Social Stress Test
Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 60 Years
Enrollment
450 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
2
States / cities
Birmingham, Alabama • Huntsville, Alabama
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 10, 2026, 8:15 PM EDT
Completed Not applicable Interventional

Study for Evaluating Different Methods of Measuring Depression Treatment Response

NCT00406952
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
electronic diary, Sertraline, Placebo, voice acoustics
Procedure · Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
12
States / cities
Norwich, Connecticut • Aventura, Florida • Jacksonville, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2008 · Synced Oct 10, 2026, 8:15 PM EDT
Recruiting Not applicable Interventional

Closed-Loop Transcranial Alternating Current Stimulation for the Treatment of Major Depressive Disorder

NCT07282678
View directory record Official record
Conditions
Depression - Major Depressive Disorder, Transcranial Alternating Current Stimulation
Interventions
Closed-loop tACS, Sham Comparator
Device
Lead sponsor
Pulvinar Neuro, LLC
Industry
Eligibility
22 Years and older
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 10, 2026, 8:15 PM EDT
Recruiting Phase 4 Interventional

Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression

NCT05892744
View directory record Official record
Conditions
Major Depressive Disorder, Chronic Major Depression, Recurrent
Interventions
Sertraline
Drug
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 10, 2026, 8:15 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Personalized Ultrasonic Brain Stimulation for Depression (R61)

NCT06902298
View directory record Official record
Conditions
Major Depressive Episode, Depression - Major Depressive Disorder, Treatment-Resistant Major Depressive Disorder
Interventions
LTFUS to SCC, LTFUS to ALIC
Device
Lead sponsor
Brian Mickey
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 10, 2026, 8:15 PM EDT
Completed Not applicable Interventional Results available

Adaptive Design Study of NEST sTMS in Subjects With Major Depressive Disorder

NCT03288714
View directory record Official record
Conditions
Depressive Disorder, Depression, Depressive Disorder, Major, Depressive Episode, Major Depressive Disorder
Interventions
Synchronized Transcranial Magnetic Stimulation (sTMS), Sham Stimulation
Device
Lead sponsor
Wave Neuroscience
Industry
Eligibility
22 Years to 65 Years
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
14
States / cities
La Jolla, California • Los Angeles, California • Stanford, California + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2021 · Synced Oct 10, 2026, 8:15 PM EDT
Terminated Phase 4 Interventional Results available

N-methyl-D-aspartate Antagonist (Ketamine) Augmentation of Electroconvulsive Treatment for Severe Major Depression

NCT01260649
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
ketamine, IV Saline, ECT, Muscle Relaxant, Anesthetic Agents
Drug · Other · Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 22, 2017 · Synced Oct 10, 2026, 8:15 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Deplin® P.L.U.S. Program (Progress Through Learning Understanding & Support)

NCT01369030
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Deplin®
Other
Lead sponsor
Pamlab, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
554 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
2
States / cities
Greensboro, North Carolina • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 3, 2014 · Synced Oct 10, 2026, 8:15 PM EDT
Completed Phase 3 Interventional

Duloxetine Versus Placebo in the Prevention of Relapse of Major Depressive Disorder

NCT00036309
View directory record Official record
Conditions
Depressive Disorder
Interventions
Duloxetine Hydrochloride
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 19, 2006 · Synced Oct 10, 2026, 8:15 PM EDT
Completed Phase 3 Interventional Results available

A Double-Blind, Placebo-Controlled Study of Aripiprazole Adjunctive to Antidepressant Therapy

NCT00683852
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Aripiprazole 5mg, Aripiprazole 2mg, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 19, 2017 · Synced Oct 10, 2026, 8:15 PM EDT
Completed Not applicable Interventional Results available

Life Goals Collaborative Care to Improve Health Outcomes in Mental Disorders

NCT01487668
View directory record Official record
Conditions
Bipolar Disorder, Schizophrenia, Major Depressive Disorder, Schizoaffective Disorder, Cardiovascular Disease Risk
Interventions
Life Goals Collaborative Care
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 99 Years
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 22, 2016 · Synced Oct 10, 2026, 8:15 PM EDT
Recruiting Phase 3 Interventional

A Study of Brenipatide in Adult Participants With Major Depressive Disorder

NCT07412756
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Brenipatide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
32
States / cities
Moorpark, California • Orange, California • New Haven, Connecticut + 29 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 10, 2026, 8:15 PM EDT